Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 18, 2013
Infrastructure resources for clinical research in amyotrophic lateral sclerosisAlexander V Sherman, Amelie K Gubitz, Ammar Al-Chalabi, et al.
Diabetologia|May 13, 2011
Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signallingR M Holmes, Z Yi, E De Filippis, et al.
Annals of Neurology|May 28, 2023
Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral SclerosisMelanie Quintana, Benjamin R Saville, Matteo Vestrucci, et al.
Annals of Neurology|December 22, 2021
Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy DevelopmentSabrina Paganoni, James D Berry, Melanie Quintana, et al.
Advanced Genetics (Hoboken, N.J.)|March 23, 2022
Community Consensus Guidelines to Support FAIR Data Standards in Clinical Research Studies in Primary Mitochondrial DiseaseAmel Karaa, Laura E MacMullen, John C Campbell, et al.
Muscle & Nerve|September 19, 2024
Access for ALL in ALS: A large-scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosisJames D Berry, Sabrina Paganoni, Matthew B Harms, et al.
Muscle & Nerve|March 21, 2025
An Expanded Access Protocol of RNS60 in Amyotrophic Lateral SclerosisGrace Addy, Erica Scirocco, Dario Gelevski, et al.
Muscle & Nerve|June 29, 2026
At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform TrialEric A Macklin, James D Berry, Brittney A Harkey, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 18, 2023
The natural history of ALS: Baseline characteristics from a multicenter clinical cohortAlex Berger, Matteo Locatelli, Ximena Arcila-Londono, et al.
Muscle & Nerve|March 17, 2023
Expanded access protocol (EAP) program for access to investigational products for amyotrophic lateral sclerosis (ALS)Megan Yerton, Allison Winter, Dario Gelevski, et al.
Pageof 9